DE69618938D1 - Nanosphären mit einem biokompatiblen polysaccharid - Google Patents

Nanosphären mit einem biokompatiblen polysaccharid

Info

Publication number
DE69618938D1
DE69618938D1 DE69618938T DE69618938T DE69618938D1 DE 69618938 D1 DE69618938 D1 DE 69618938D1 DE 69618938 T DE69618938 T DE 69618938T DE 69618938 T DE69618938 T DE 69618938T DE 69618938 D1 DE69618938 D1 DE 69618938D1
Authority
DE
Germany
Prior art keywords
microspheres
preparation
nanospheres
bio
carriers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69618938T
Other languages
English (en)
Other versions
DE69618938T2 (de
Inventor
Paolo Pallado
Luca Benedetti
Lanfranco Callegaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Original Assignee
Fidia Advanced Biopolymers SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95PD000065A external-priority patent/IT1281857B1/it
Priority claimed from IT96PD000021 external-priority patent/IT1287194B1/it
Application filed by Fidia Advanced Biopolymers SRL filed Critical Fidia Advanced Biopolymers SRL
Application granted granted Critical
Publication of DE69618938D1 publication Critical patent/DE69618938D1/de
Publication of DE69618938T2 publication Critical patent/DE69618938T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
DE69618938T 1995-03-28 1996-03-26 Nanosphären mit einem biokompatiblen polysaccharid Expired - Lifetime DE69618938T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT95PD000065A IT1281857B1 (it) 1995-03-28 1995-03-28 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici.
IT96PD000021 IT1287194B1 (it) 1996-02-05 1996-02-05 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici
PCT/EP1996/001354 WO1996029998A1 (en) 1995-03-28 1996-03-26 Nanospheres comprising a biocompatible polysaccharide
US08/938,288 US6214384B1 (en) 1995-03-28 1997-09-26 Nanosheres comprising a biocompatible polysaccharide

Publications (2)

Publication Number Publication Date
DE69618938D1 true DE69618938D1 (de) 2002-03-14
DE69618938T2 DE69618938T2 (de) 2002-10-31

Family

ID=27274135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69618938T Expired - Lifetime DE69618938T2 (de) 1995-03-28 1996-03-26 Nanosphären mit einem biokompatiblen polysaccharid

Country Status (8)

Country Link
US (2) US6214384B1 (de)
EP (1) EP0817620B1 (de)
AT (1) ATE212545T1 (de)
AU (1) AU695207B2 (de)
CA (1) CA2216919C (de)
DE (1) DE69618938T2 (de)
ES (1) ES2170853T3 (de)
WO (1) WO1996029998A1 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
AU717113B2 (en) 1995-11-09 2000-03-16 Health Protection Agency Microencapsulated DNA for vaccination and gene therapy
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
DE19711393C1 (de) * 1997-03-19 1998-08-13 Fraunhofer Ges Forschung Verfahren zum Mikroverkapseln von Partikeln
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6045815A (en) 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
EP1073419A4 (de) * 1998-03-18 2009-03-25 Univ Technology Corp Zusammensetzung, enthaltend amorphes polymer, zur verzögerten freisetzung.
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
CA2335460A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
SE9804000D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New composition of matter
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
IT1306644B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
GB9927011D0 (en) * 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
CH694686A5 (it) * 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
ATE362382T1 (de) 2000-03-15 2007-06-15 Orbusneich Medical Inc Beschichtung welche ein anhaften von endothelzellen stimuliert
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) * 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7883490B2 (en) * 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
EP1711163A2 (de) * 2004-02-05 2006-10-18 Baxter International Inc. Unter verwendung von selbststabilisierenden mitteln hergestellte dispersionen
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
WO2005107817A2 (en) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US7311861B2 (en) * 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7384879B2 (en) 2004-09-27 2008-06-10 Auburn University Selection and deposition of nanoparticles using CO2-expanded liquids
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) * 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
DE602006010072D1 (de) 2005-06-21 2009-12-10 Chen Gang Il-1 bindende antikörper und fragmente davon
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
AU2007240986A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
EP2094306A2 (de) 2006-12-20 2009-09-02 XOMA Technology Ltd. Behandlung von il-1-beta-bedingten erkrankungen
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
WO2009015286A2 (en) * 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
US8215489B1 (en) 2008-10-31 2012-07-10 Auburn University Method and apparatus for physical separation of different sized nanostructures
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ITRM20110008A1 (it) * 2011-01-12 2012-07-13 Alfonso Barbarisi Procedimento per la partecipazione di nanoparticelle reticolate a base di estere benzilico dell'acido ialuronico da utilizzare come vettori per il rilascio controllato di principi attivi
EP2680827B1 (de) * 2011-03-04 2020-01-08 Institut National de la Santé et de la Recherche Médicale Teilchen mit einem wachstumsfaktor und ihre verwendung
TWI419701B (zh) * 2011-11-08 2013-12-21 包覆生長因子之多醣體微粒子
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP2802601B1 (de) 2012-01-09 2019-11-13 The Scripps Research Institute Humanisierte antikörper mit ultralangem cdr3s
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2838653A4 (de) * 2012-04-18 2015-11-25 Cerulean Pharma Inc Verfahren und systeme zur polymerausfällung und erzeugung von teilchen
WO2014005103A2 (en) 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
EP3057994B1 (de) 2013-10-15 2020-09-23 The Scripps Research Institute Chimäre peptidische antigenrezeptor-t-zell-schalter und verwendungen davon
EP4212180A1 (de) 2013-12-18 2023-07-19 The Scripps Research Institute Modifizierte therapeutika, geklammerte peptidlipidkonjugate und zusammensetzungen davon
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
TW202120551A (zh) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
EP4048405A2 (de) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimäre cytokin-modifizierte antikörper und verfahren zu deren verwendung
EP4329887A1 (de) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanisierte chimäre rinderantikörper und verfahren zur verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances
EP0093757A1 (de) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Verfahren zur herstellung von magnetisch beeinflussbaren nanopartikeln für intravaskulare anwendung
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
JP2843857B2 (ja) * 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー 反溶剤への沈澱を介する微細分化固体結晶性粉末
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles

Also Published As

Publication number Publication date
US6541035B1 (en) 2003-04-01
US6214384B1 (en) 2001-04-10
AU695207B2 (en) 1998-08-06
EP0817620A1 (de) 1998-01-14
AU5274996A (en) 1996-10-16
DE69618938T2 (de) 2002-10-31
EP0817620B1 (de) 2002-01-30
WO1996029998A1 (en) 1996-10-03
ATE212545T1 (de) 2002-02-15
CA2216919C (en) 2007-09-18
ES2170853T3 (es) 2002-08-16
CA2216919A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
DE69618938D1 (de) Nanosphären mit einem biokompatiblen polysaccharid
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
HUP0003013A2 (hu) Eljárás és készítmények késői fázisban lévő allergiás reakciók és gyulladásos megbetegedések kezelésére
UA48946C2 (uk) Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
PL316416A1 (en) Pharmaceutic agent exhibiting immunoregulating and psychotropic properties, therapeutic form thereof and method of treating diseases of immunological and physical background
Sheshala et al. Formulation and characterization of pH induced in situ gels containing sulfacetamide sodium for ocular drug delivery: A combination of Carbopol®/HPMC polymer
ATE234341T1 (de) Dreidimensionale struktur enthaltend hyaluronsäurederivat, hergestellt durch die technik von superkritischen antilösungsmitteln
DE69824748D1 (de) Pharmazeutische zusammensetzung für die behandlung von enzündlichen darmerkrankungen
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
CN105982912A (zh) 一种包含透明质酸钠和硫酸软骨素的药物组合物
Taysi et al. A new syndrome of proximal deletion of the long arm of chromosome 1: 1q21–23→ 1q25
ATE193297T1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
RS51420B (en) HYPERSTRUCTURE AMYLOPECTIN FOR USE IN THE PROCEDURES OF SURGICAL OR THERAPEUTIC TREATMENT OF mammals OR IN THE PROCEDURES OF DIAGNOSIS, AND PARTICULARLY FOR USE AS A PLASMA VOLUME EXPANDER
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
CA2369275A1 (en) Process for the preparation of autocrosslinked compounds of hyaluronic acid and the derivatives thereof by the supercritical antisolvent technique
ATE226069T1 (de) Verwendung von alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur behandlung von entzündlichen darmerkrankungen
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
Wilcox et al. Is oral acyclovir effective in preventing postherpetic neuralgia?
Ulanov The comparative clinico-epidemiological characteristics of schizophrenia patients living in urban and rural localities
van Donselaar et al. Reliability of the diagnosis of a first seizure [1]
Fisher JAMA and Pharmaceutical Advertising

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: FIDIA FARMACEUTICI S.P.A., ABANO TERME, PADUA/PADO

8328 Change in the person/name/address of the agent

Representative=s name: SEITZ, R., DIPL.-ING.UNIV., PAT.-ANW., 80538 MUENC